China Medical System Holdings Limited (HKG:0867)
Hong Kong · Delayed Price · Currency is HKD 11.30
-0.04 (-0.35%)
May 19, 2026, 1:04 PM HKT
China Medical System Holdings Employees
China Medical System Holdings had 6,415 employees as of December 31, 2025. The number of employees increased by 274 or 4.46% compared to the previous year.
Employees
6,415
Change (1Y)
274
Growth (1Y)
4.46%
Revenue / Employee
1.42M HKD
Profits / Employee
258.28K HKD
Market Cap
27.45B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 6,415 | 274 | 4.46% |
| Dec 31, 2024 | 6,141 | 440 | 7.72% |
| Dec 31, 2023 | 5,701 | 54 | 0.96% |
| Dec 31, 2022 | 5,647 | 355 | 6.71% |
| Dec 31, 2021 | 5,292 | 920 | 21.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| China Resources Pharmaceutical Group | 85,600 |
| The United Laboratories International Holdings | 18,000 |
| Grand Pharmaceutical Group | 12,614 |
| Simcere Pharmaceutical Group | 6,815 |
| Sunshine Lake Pharma | 6,353 |
| Consun Pharmaceutical Group | 3,073 |
| Sihuan Pharmaceutical Holdings Group | 2,767 |
| CanSino Biologics | 1,134 |
China Medical System Holdings News
- 2 months ago - China Medical System reports NMPA acceptance of ruxolitinib phosphate cream NDA - TheFly
- 5 months ago - China Medical says povorcitinib included in Breakthrough Therapeutic Drugs list - TheFly
- 5 months ago - CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China - GlobeNewsWire
- 5 months ago - China Medical System announces NMPA acceptance of Y-3 NDA - TheFly
- 7 months ago - China Medical System announces NMPA acceptance of MG-K10 NDA - TheFly
- 7 months ago - CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu® - GlobeNewsWire
- 8 months ago - China Medical announces Phase 3 ruxolitinib trial met primary endpoint - TheFly
- 10 months ago - China Medical System announces NMPA acceptance of ZUNVEYL NDA - TheFly